CCL2 and neoplasm: Activation of β-ARs in tumor cells and immune cells directly silenced the CCL2 expression, leading to an immunosuppressive tumor microenvironment and a significant enhancement of checkpoint blockade-refractory tumor response to anti-PD-L1 therapy (Fig. 6L).